<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Profusa, Inc. — News on 6ix</title>
<link>https://6ix.com/company/profusa-inc</link>
<description>Latest news and press releases for Profusa, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 06 Apr 2026 10:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/profusa-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7785c51cc36e47533fca8.webp</url>
<title>Profusa, Inc.</title>
<link>https://6ix.com/company/profusa-inc</link>
</image>
<item>
<title>Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-expands-into-multi-billion-dollar-precision-diagnostics-market-with-dollar30m-letter-of-intent-for-a-panomics-platform</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-expands-into-multi-billion-dollar-precision-diagnostics-market-with-dollar30m-letter-of-intent-for-a-panomics-platform</guid>
<pubDate>Mon, 06 Apr 2026 10:00:00 GMT</pubDate>
<description>Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERKELEY, CA, April 06, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, today announced a strategic expa</description>
</item>
<item>
<title>Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-to-withdraw-s-1-registration-statement-to-pursue-a-smaller-more-focused-offering</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-to-withdraw-s-1-registration-statement-to-pursue-a-smaller-more-focused-offering</guid>
<pubDate>Fri, 27 Feb 2026 14:15:00 GMT</pubDate>
<description>After Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to Achieve Near-term Revenue Projections BERKELEY, CA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemis</description>
</item>
<item>
<title>Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-receives-purchase-orders-for-lumeetm-tissue-oxygen-monitoring-and-raises-2026-revenue-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-receives-purchase-orders-for-lumeetm-tissue-oxygen-monitoring-and-raises-2026-revenue-guidance</guid>
<pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
<description>With strong underlying market demand, European distributor and expert physician customer purchase orders are being received by the Company as its 2026 revenue</description>
</item>
<item>
<title>Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-and-mayo-clinic-collaborate-to-advance-high-impact-clinical-applications-of-oxygen-monitoring-technologies</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-and-mayo-clinic-collaborate-to-advance-high-impact-clinical-applications-of-oxygen-monitoring-technologies</guid>
<pubDate>Fri, 13 Feb 2026 13:30:00 GMT</pubDate>
<description>Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new tethered continuous oxygen monitoring products for high impact clinical applications BERKELEY, Calif, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform seeking to en</description>
</item>
<item>
<title>Profusa Announces 1-for-75 Reverse Stock Split</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-announces-1-for-75-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-announces-1-for-75-reverse-stock-split</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company</description>
</item>
<item>
<title>Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-presents-positive-us-study-clinical-results-at-leipzig-interventional-course-linc-2026</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-presents-positive-us-study-clinical-results-at-leipzig-interventional-course-linc-2026</guid>
<pubDate>Thu, 29 Jan 2026 13:00:00 GMT</pubDate>
<description>Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients BERKELEY, Calif, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the presentation of positive US-study clinical trial results at Leipzig Interventional Course in Leipgzig, Germany on Wednesday, Ja</description>
</item>
<item>
<title>Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-launches-lumeetm-tissue-oxygen-healthcare-research-offerings-initiating-first-commercial-revenue</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-launches-lumeetm-tissue-oxygen-healthcare-research-offerings-initiating-first-commercial-revenue</guid>
<pubDate>Fri, 16 Jan 2026 05:00:00 GMT</pubDate>
<description>Research-use-only offerings are commercially available, enabling immediate product and service revenue generation Targets the global CRO market of $47.9</description>
</item>
<item>
<title>Profusa Adds Leading Greek Vascular Surgeon to Customer Base</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-adds-leading-greek-vascular-surgeon-to-customer-base</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-adds-leading-greek-vascular-surgeon-to-customer-base</guid>
<pubDate>Thu, 08 Jan 2026 12:30:00 GMT</pubDate>
<description>Dr. Theodosios Bisdas is a renowned vascular surgeon and Head of Clinic of Vascular Surgery at the Athens Medical Center BERKELEY, Calif, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces a collaboration with Theodosios Bisdas, M.D., Ph.D., FACS, Head of Clinic of Vascular Surgery,</description>
</item>
<item>
<title>Profusa Bolsters European Commercial Network with New French Distributor, MedSell</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-bolsters-european-commercial-network-with-new-french-distributor-medsell</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-bolsters-european-commercial-network-with-new-french-distributor-medsell</guid>
<pubDate>Wed, 31 Dec 2025 12:30:00 GMT</pubDate>
<description>MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now reach approximately 200,000 annual CLI cases in the European Union Agreement complements KOL collaboration with Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris that accounts for approximately 8% of all CLTI cases in France BERKELEY, Calif, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Profusa, I</description>
</item>
<item>
<title>Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-restructures-senior-secured-convertible-notes-only-convertible-above-dollar035</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-restructures-senior-secured-convertible-notes-only-convertible-above-dollar035</guid>
<pubDate>Tue, 30 Dec 2025 12:30:00 GMT</pubDate>
<description>New note provides greater repayment flexibility and less dilution with elimination of mandatory amortization payments, increased conversion floor price to $0.35, and expanded mandatory ELOC payments from 33% to 50% BERKELEY, Calif, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the re</description>
</item>
<item>
<title>Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-us-study-met-primary-end-points-as-presented-at-late-breaking-clinical-trials-at-paris-vascular-insights-2025</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-us-study-met-primary-end-points-as-presented-at-late-breaking-clinical-trials-at-paris-vascular-insights-2025</guid>
<pubDate>Mon, 15 Dec 2025 12:30:00 GMT</pubDate>
<description>Data from FDA-advised study demonstrates Lumee™ Oxygen tissue monitoring is a safe and effective long-term method in PAD patients and will support potential FDA submission; strongly correlates with transcutaneous partial pressure of oxygen BERKELEY, Calif, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s bioch</description>
</item>
<item>
<title>Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026</guid>
<pubDate>Thu, 11 Dec 2025 13:30:00 GMT</pubDate>
<description>Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients BERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the acceptance of their abstract at the upcoming Leipzig Interventional Course (LINC) 2026, being held January 27-30, 2026, in Leip</description>
</item>
<item>
<title>Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-to-present-late-breaking-us-based-clinical-trial-update-at-paris-vascular-insights-2025</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-to-present-late-breaking-us-based-clinical-trial-update-at-paris-vascular-insights-2025</guid>
<pubDate>Mon, 24 Nov 2025 13:15:00 GMT</pubDate>
<description>Study evaluates Lumee™ Oxygen tissue monitoring platform with transcutaneous partial pressure of oxygen (tcpO₂) in peripheral artery disease patients BERKELEY, Calif, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the acceptance of an abstract for a Late Breaking Clinical Trial Update</description>
</item>
<item>
<title>Profusa Announces Third Quarter Business and Financial Highlights</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-announces-third-quarter-business-and-financial-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-announces-third-quarter-business-and-financial-highlights</guid>
<pubDate>Wed, 19 Nov 2025 22:44:00 GMT</pubDate>
<description>Recapitalization reduced net debt to $14 million as of October 31; achieved key milestones to deliver potential 2026 revenue target BERKELEY, Calif, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces financial results for the third quarter ended September 30, 2025, and provides business h</description>
</item>
<item>
<title>Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-outlines-potential-path-to-dollar250-million-revenue-by-2030-driven-by-sequential-lumeetm-oxygen-and-glucose-monitoring-launches</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-outlines-potential-path-to-dollar250-million-revenue-by-2030-driven-by-sequential-lumeetm-oxygen-and-glucose-monitoring-launches</guid>
<pubDate>Thu, 30 Oct 2025 11:30:00 GMT</pubDate>
<description>EU commercialization expected in early 2026; U.S. entry and expanded indications to follow as digital-health pioneer advances tissue-integrated biosensor platform BERKELEY, Calif, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, outlines its path to revenue generation led by Lumee tissue oxygen m</description>
</item>
<item>
<title>Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-completes-manufacturing-build-out-on-track-to-begin-product-shipments-and-revenue-in-early-2026</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-completes-manufacturing-build-out-on-track-to-begin-product-shipments-and-revenue-in-early-2026</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>Achieved key operational milestones establishing manufacturing capabilities to supply more than 2x the products required to achieve 2026 revenue targets</description>
</item>
<item>
<title>Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-expands-sales-footprint-with-new-distributor-for-lumeetm-oxygen-platform-in-europe</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-expands-sales-footprint-with-new-distributor-for-lumeetm-oxygen-platform-in-europe</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia Expands distributor channel</description>
</item>
<item>
<title>Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-adds-a-leading-french-critical-limb-ischemia-surgeon-to-customer-base</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-adds-a-leading-french-critical-limb-ischemia-surgeon-to-customer-base</guid>
<pubDate>Wed, 01 Oct 2025 12:30:00 GMT</pubDate>
<description>Pr. Yann Gouëffic and affiliates (FRANCE-PAD) cover ~8% of all CLTI cases in France BERKELEY, Calif, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces additional growth in its customer base in Europe, with a collaboration with Yann Gouëffic, M.D., Ph.D., professor of vascular surgery in</description>
</item>
<item>
<title>Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-adopts-nvidia-powered-technology-to-build-ai-driven-insight-portal-for-continuous-biomarker-monitoring</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-adopts-nvidia-powered-technology-to-build-ai-driven-insight-portal-for-continuous-biomarker-monitoring</guid>
<pubDate>Thu, 11 Sep 2025 12:30:00 GMT</pubDate>
<description>Company expects early 2026 rollout in EEA; physician portal combines Lumee™ oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical workflows BERKELEY, Calif, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the adoption of NVIDIA technology to power an AI-driven insight porta</description>
</item>
<item>
<title>Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base</title>
<link>https://6ix.com/company/profusa-inc/news/profusa-adds-head-of-vascular-surgery-department-at-az-sint-blasius-hospital-belgium-to-growing-customer-base</link>
<guid isPermaLink="true">https://6ix.com/company/profusa-inc/news/profusa-adds-head-of-vascular-surgery-department-at-az-sint-blasius-hospital-belgium-to-growing-customer-base</guid>
<pubDate>Thu, 04 Sep 2025 12:30:00 GMT</pubDate>
<description>Internationally recognized vascular surgeon, Dr. Koen Deloose provides patient access to latest innovative treatments and personalized care BERKELEY, Calif, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces continued growth in its customer base in Europe, with a new commercial and clini</description>
</item>
</channel>
</rss>